Showing results (111-120 of 123) with videos related to
Sort By:
Pageof 13
Clinical Drug Investigation|January 27, 2026
Efficacy of Brexpiprazole in Participants with Agitation Associated with Dementia Due to Alzheimer's Disease: Pooled Analysis of Randomized Controlled TrialsJeffrey L Cummings, Sanjeda R Chumki, Denise Chang, et al.JAMA Neurology|November 6, 2023
Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical TrialDaniel Lee, Mary Slomkowski, Nanco Hefting, et al.Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|December 1, 2016
Ideomotor limb apraxia as a staging tool in individuals with Alzheimer's disease (ILIAD)William D Soulsby, Nezar El-Ruwie, Shravan Gatla, et al.Current Medical Research and Opinion|August 23, 2025
Brexpiprazole for agitation in clinically relevant patient subgroups: a <i>post hoc</i> analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer's diseaseJared Stroud, Jeffrey L Cummings, Sanjeda R Chumki, et al.The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|November 12, 2019
Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled TrialsGeorge T Grossberg, Eva Kohegyi, Victor Mergel, et al.Brain : a Journal of Neurology|June 1, 2018
The cholinergic system in the pathophysiology and treatment of Alzheimer's diseaseHarald Hampel, M-Marsel Mesulam, A Claudio Cuello, et al.CNS Drugs|July 18, 2025
Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer's Disease: Pooled Analysis of Three Randomized Trials and an Extension TrialAlpesh Shah, Alvin Estilo, Pamela L Sheridan, et al.CNS Drugs|June 5, 2013
The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitorsGeorge T Grossberg, Facundo Manes, Ricardo F Allegri, et al.The Journal of Clinical Psychiatry|May 23, 2008
Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policyCarl Salzman, Dilip V Jeste, Roger E Meyer, et al.Journal of the American Medical Directors Association|April 8, 2014
International survey of nursing home research prioritiesJohn E Morley, Gideon Caplan, Matteo Cesari, et al.Pageof 13